Medical University of Vienna Background
Aortic aneurysms affecting the thoracic aorta have an estimated incidence of 5-10 per 100,000 person-years. Regarding the prevalence of this disease, an exact number is difficult to define as the disease is asymptomatic over a long period of time (decades) before fatal rupture occurs. Due to its silent progression and the lethal nature of the disease due to acute rupture or dissection, thoracic aortic aneurysm is an important vascular disease which needs a new screening strategy for early detection and improved monitoring.
To date, there are no clinically valid biomarkers available used for the detection and monitoring of aneurysms of the thoracic aorta. Accordingly, there is still a need in the art for reliable detection and monitoring of aneurysms of the thoracic aorta, in particular of BAV and/or BAV aneurysms.
The invention relates to novel biomarkers that determine the oxidative state/status and/or the anti-oxidative capacity in a sample from said patient in a blood, serum, skin, respiration air or urine sample.
Non-invasive, sample from blood and other body fluids
quick and cheap
Prediction for patients to immediately seek examination via imaging methods
Development of a reactivity test kit